Approved Risk Evaluation and Mitigation Strategies (REMS)
REMS that have more than one drug product but are not Shared System REMS will not display the product name and ingredient properly on this website due to database limitations. Please refer to the REMS document for the correct product names.
Tryvio (aprocitentan)What is the purpose of the REMS?
The goal of the TRYVIO (aprocitentan) REMS is to mitigate the risk of embryo-fetal toxicity associated with TRYVIO.- Objective: Ensure that prescribers are aware of the risk of embryo-fetal toxicity associated with
TRYVIO and the need to counsel patients who can become pregnant on the actions
necessary to prevent pregnancy and minimize exposure to a fetus.
What do participants need to know?
Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the application holder(s) REMS Website or the approved REMS materials for more information.
What assessment is available to the REMS?
Assessment Plan |
---|
REMS assessment plan unavailable for posting at this time. |
What updates have been made to the REMS?
Date | Summary of change |
---|---|
03/19/2024 | Approval of the REMS |
Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.